Prabhudas Liladhar

Godawari Power Buy Call by Emkay Global; Prabhudas Lilladher Bets on Divis Labs

Godawari Power Buy Call by Emkay Global; Prabhudas Lilladher Bets on Divis LabsEmkay Global Financial Services has given target price of Rs 143 for Godavari Power and Ispat. The analyst house has given bullish outlook for the power and metals sector company based on good growth during the previous quarter.

The business has improved and 102% higher iron ore mining compared to same period of previous year. Emkay Global has given buy call for the stock.

Several Brokerages Give Buy Call for IndusInd Bank; Market Ends Higher

Several Brokerages Give Buy Call for IndusInd Bank; Market Ends HigherSeveral major brokerage houses have given a buy call for private banking major IndusInd Bank. Nirmal Bang has given buy call with target price of Rs 413 in October research report. The bank has announced results as per analyst expectations and stock closed at Rs 363 today.

Prabhudas Lilladher gave buy rating to the stock with target price of Rs 400. The report expressed satisfaction over asset quality of the bank and lower credit cost during the first half of financial year.

Private Banking Majors to Declare Results Coming Week

Private Banking Majors to Declare Results Coming WeekKotak Mahindra Bank will soon be announcing quarterly results. The fast growing private bank is expected to declare positive results as per estimates of recent report by Prabhudas Lilladher. Kotak Mahindra Bank is currently trading with a P/E multiple of 41 and is hovering around its 52-week high of 612 on NSE.

Ranbaxy to Launch Dermatology Drug Absorica in US Market

Ranbaxy to Launch Dermatology Drug Absorica in US MarketPharmaceutical major Ranbaxy Laboratories in planning to launch Absorica in US market by the end of year. Ranbaxy has shown stellar performance in the past quarterly result and the stock price has seen significant jump in valuations.

Cipher Pharma, the company having patented brand formulation of the acne medication isotretinoin, will receive $9 million from Ranbaxy Laboratories as per media reports.

The stock price on NSE was down by 0.6% at Rs 526. The company has touched 52-week high and low of Rs 570 and 365 respectively.

Buy DLF With Stop Loss Of Rs 315

Buy DLF With Stop Loss Of Rs 315Stock market analyst Prabhudas Liladhar has maintained 'buy' rating on DLF Ltd stock with a target of Rs 342.

According to analyst, the interested investors can buy the stock with strict stop loss of Rs 315.

Today, the stock of the company opened at Rs 322 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 490.80 and a low of Rs 259 on BSE.

Current EPS & P/E ratio stood at 10.76 and 29.87 respectively.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content